Show simple item record

dc.contributor.authorKelly, Vincenten
dc.contributor.authorGhanim, Magdaen
dc.contributor.authorMc Manus, Gavinen
dc.contributor.authorMok, Kennethen
dc.date.accessioned2022-02-14T15:11:52Z
dc.date.available2022-02-14T15:11:52Z
dc.date.issued2021en
dc.date.submitted2021en
dc.identifier.citationGhanim M, Relitti N, McManus G, Butini S, Cappelli A, Campiani G, Mok KH, Kelly VP, A non-toxic, reversibly released imaging probe for oral cancer that is derived from natural compounds., Scientific reports, 2021en
dc.identifier.otherYen
dc.descriptionPUBLISHEDen
dc.description.abstractCD44 is emerging as an important receptor biomarker for various cancers. Amongst these is oral cancer, where surgical resection remains an essential mode of treatment. Unfortunately, surgery is frequently associated with permanent disfigurement, malnutrition, and functional comorbidities due to the difficultly of tumour removal. Optical imaging agents that can guide tumour tissue identification represent an attractive approach to minimising the impact of surgery. Here, we report the synthesis of a water‑soluble fluorescent probe, namely HA‑FA‑HEG‑OE (compound 1), that comprises components originating from natural sources: oleic acid, ferulic acid and hyaluronic acid. Compound 1 was found to be non‑toxic, displayed aggregation induced emission and accumulated intracellularly in vesicles in SCC‑9 oral squamous cells. The uptake of 1 was fully reversible over time. Internalization of compound 1 occurs through receptor mediated endocytosis; uniquely mediated through the CD44 receptor. Uptake is related to tumorigenic potential, with non‑tumorigenic, dysplastic DOK cells and poorly tumorigenic MCF‑7 cells showing only low intracellular levels and highlighting the critical role of endocytosis in cancer progression and metastasis. Together, the recognised importance of CD44 as a cancer stem cell marker in oral cancer, and the reversible, non‑toxic nature of 1, makes it a promising agent for real time intraoperative imaging.en
dc.language.isoenen
dc.relation.ispartofseriesScientific reportsen
dc.rightsYen
dc.subjectCD44en
dc.subjectcancersen
dc.subjectHA‑FA‑HEG‑OE (compound 1)en
dc.subject.lcshCD44en
dc.subject.lcshcancersen
dc.subject.lcshHA‑FA‑HEG‑OE (compound 1)en
dc.titleA non-toxic, reversibly released imaging probe for oral cancer that is derived from natural compounds.en
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/kellyvpen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/mok1en
dc.identifier.peoplefinderurlhttp://people.tcd.ie/mghanimen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/mcmanugen
dc.identifier.rssinternalid232214en
dc.identifier.doihttps://doi.org/10.1038/s41598-021-93408-0en
dc.relation.ecprojectidinfo:eu-repo/grantAgreement/EC/FP7/721906-TRACT
dc.rights.ecaccessrightsopenAccess
dc.subject.TCDThemeCanceren
dc.subject.TCDTagCANCERen
dc.subject.TCDTagCANCER CELLSen
dc.subject.TCDTagCancer Detectionen
dc.subject.TCDTagCancer Screeningen
dc.identifier.orcid_id0000-0001-7067-5407en
dc.subject.darat_thematicHealthen
dc.status.accessibleNen
dc.contributor.sponsorOtheren
dc.contributor.sponsorGrantNumberPOR-FSE 2014-2020en
dc.contributor.sponsorEuropean Union (EU)en
dc.contributor.sponsorGrantNumber721906-TRACTen
dc.identifier.urihttp://hdl.handle.net/2262/98094


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record